IMMUNITYBIO, INC. Increase (Decrease) in Prepaid Expense and Other Assets
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2025-03-03
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2024-12-31 was -$1.33M, a 138.03% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2024-09-30 was $2.78M, a 56.33% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2024-06-30 was -$1.51M.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2024-03-31 was -$1.63M.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.70M.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$5.96M, a 135.98% decline from fiscal 2022.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $16.56M, a 636.19% increase from fiscal 2021.
- IMMUNITYBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $2.25M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.45M derived: sum of 2 quarters · filed 2025-03-03 | -$69.00K derived: sum of 3 quarters · filed 2025-03-03 | -$1.70M 10-K · filed 2025-03-03 | ||||
| 2024-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.26M derived: sum of 2 quarters · filed 2024-11-12 | -$370.00K 10-Q · filed 2024-11-12 | $3.13M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.15M 10-Q · filed 2024-08-12 | $357.00K derived: sum of 3 quarters · filed 2025-03-03 | $2.13M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-03-31 | -$1.63M 10-Q · filed 2024-05-09 | $1.87M derived: sum of 2 quarters · filed 2025-03-03 | $3.65M derived: sum of 3 quarters · filed 2025-03-03 | $2.10M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $5.28M derived: sum of 2 quarters · filed 2025-03-03 | $3.73M derived: sum of 3 quarters · filed 2025-03-03 | -$5.96M 10-K · filed 2025-03-03 | ||||
| 2023-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $226.00K derived: sum of 2 quarters · filed 2024-11-12 | -$9.46M 10-Q · filed 2024-11-12 | -$7.33M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$11.24M 10-Q · filed 2024-08-12 | -$9.10M derived: sum of 3 quarters · filed 2025-03-03 | -$9.16M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | -$9.69M 10-Q · filed 2024-05-09 | -$7.55M derived: sum of 2 quarters · filed 2025-03-03 | -$7.61M derived: sum of 3 quarters · filed 2025-03-03 | $6.65M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.08M derived: sum of 2 quarters · filed 2025-03-03 | $16.34M derived: sum of 3 quarters · filed 2025-03-03 | $16.56M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.20M derived: sum of 2 quarters · filed 2023-11-09 | $14.42M 10-Q · filed 2023-11-09 | $17.09M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $14.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $14.47M 10-Q · filed 2023-08-08 | $17.15M derived: sum of 3 quarters · filed 2024-03-19 | $22.14M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $218.00K 10-Q · filed 2023-05-11 | $2.89M derived: sum of 2 quarters · filed 2024-03-19 | $7.89M derived: sum of 3 quarters · filed 2024-03-19 | $1.53M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $7.67M derived: sum of 2 quarters · filed 2024-03-19 | $1.31M derived: sum of 3 quarters · filed 2024-03-19 | $2.25M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.36M derived: sum of 2 quarters · filed 2022-11-09 | -$425.00K 10-Q · filed 2022-11-09 | -$11.40M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | -$6.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$5.42M 10-Q · filed 2022-08-08 | -$16.40M derived: sum of 3 quarters · filed 2023-03-01 | -$15.26M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $934.00K 10-Q · filed 2022-05-10 | -$10.04M derived: sum of 2 quarters · filed 2023-03-01 | -$8.91M derived: sum of 3 quarters · filed 2023-03-01 | -$7.29M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$10.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$9.84M derived: sum of 2 quarters · filed 2023-03-01 | -$8.23M derived: sum of 3 quarters · filed 2023-03-01 | -$4.21M 10-K · filed 2023-03-01 | $1.33M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.75M derived: sum of 2 quarters · filed 2021-11-12 | $6.77M 10-Q · filed 2021-11-12 | $2.29M 10-Q · filed 2020-11-09 | $10.11M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $5.63M 10-Q · filed 2021-08-12 | -$927.00K 10-Q · filed 2020-08-07 | $8.97M derived: sum of 3 quarters · filed 2022-03-01 | $10.64M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $4.02M 10-Q · filed 2021-05-14 | -$244.00K 10-Q · filed 2020-05-11 | $7.36M derived: sum of 2 quarters · filed 2022-03-01 | $9.03M derived: sum of 3 quarters · filed 2022-03-01 | -$1.74M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.01M derived: sum of 2 quarters · filed 2022-03-01 | -$5.76M derived: sum of 3 quarters · filed 2022-03-01 | -$5.84M 10-K · filed 2022-03-01 | -$9.28M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$9.10M derived: sum of 2 quarters · filed 2020-11-09 | -$9.18M 10-Q · filed 2020-11-09 | -$6.21M 10-Q · filed 2019-11-05 | -$13.03M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | -$10.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$10.84M 10-Q · filed 2020-08-07 | -$10.86M 10-Q · filed 2019-08-06 | -$14.70M derived: sum of 3 quarters · filed 2021-03-04 | -$1.56M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | -$80.00K 10-Q · filed 2020-05-11 | -$88.00K 10-Q · filed 2019-05-08 | -$3.93M derived: sum of 2 quarters · filed 2021-03-04 | $9.21M derived: sum of 3 quarters · filed 2021-03-04 | $8.89M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $9.29M derived: sum of 2 quarters · filed 2021-03-04 | $8.97M derived: sum of 3 quarters · filed 2021-03-04 | $9.82M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $13.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $12.82M derived: sum of 2 quarters · filed 2019-11-05 | $13.67M 10-Q · filed 2019-11-05 | $12.45M 10-Q · filed 2018-11-07 | $12.94M derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-06-30 | -$315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $532.00K 10-Q · filed 2019-08-06 | $544.00K 10-Q · filed 2018-08-06 | -$200.00K derived: sum of 3 quarters · filed 2020-03-25 | -$930.00K derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-03-31 | $847.00K 10-Q · filed 2019-05-08 | $115.00K derived: sum of 2 quarters · filed 2020-03-25 | -$615.00K derived: sum of 3 quarters · filed 2020-03-25 | $678.00K derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | -$732.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$1.46M derived: sum of 2 quarters · filed 2020-03-25 | -$169.00K derived: sum of 3 quarters · filed 2020-03-25 | -$156.00K 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | -$730.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $563.00K derived: sum of 2 quarters · filed 2018-11-07 | $576.00K 10-Q · filed 2018-11-07 | $654.00K derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $1.31M 10-Q · filed 2018-08-06 | $1.38M derived: sum of 3 quarters · filed 2019-03-13 | $2.41M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | $13.00K 10-Q · filed 2018-05-07 | $91.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.12M derived: sum of 3 quarters · filed 2019-03-13 | $1.31M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $1.10M derived: sum of 2 quarters · filed 2019-03-13 | $1.30M derived: sum of 3 quarters · filed 2019-03-13 | $1.46M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.22M derived: sum of 2 quarters · filed 2017-11-07 | $1.38M 10-Q · filed 2017-11-07 | $3.15M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $355.00K 10-Q · filed 2016-08-15 | $2.12M derived: sum of 3 quarters · filed 2018-03-12 | $3.29M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $160.00K 10-Q · filed 2017-05-08 | $1.93M derived: sum of 2 quarters · filed 2018-03-12 | $3.09M derived: sum of 3 quarters · filed 2018-03-12 | $3.46M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2015-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $2.93M derived: sum of 2 quarters · filed 2018-03-12 | $3.30M derived: sum of 3 quarters · filed 2018-03-12 | $3.23M 10-K · filed 2018-03-12 | $3.31M 10-K · filed 2016-03-30 | |||
| 2015-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.53M derived: sum of 2 quarters · filed 2016-11-10 | $1.46M 10-Q · filed 2016-11-10 | $1.58M 10-Q · filed 2015-11-12 | $1.54M derived: sum of 4 quarters · filed 2016-11-10 | |||
| 2015-06-30 | $371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $300.00K 10-Q · filed 2016-08-15 | $382.00K derived: sum of 3 quarters · filed 2016-08-15 | |||||
| 2015-03-31 | -$71.00K 10-Q · filed 2016-05-16 | $11.00K derived: sum of 2 quarters · filed 2016-05-16 | ||||||
| 2014-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $14.00K 10-K · filed 2016-03-30 | ||||||
| 2014-09-30 | -$68.00K 10-Q · filed 2015-11-12 | |||||||
| 2013-12-31 | -$97.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |